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for surgery and VTEs were extracted for 49 days post-HFR.
Logistic regressions (LR) with covariates of congestive heart
failure, obesity, cancer, age, and gender were performed
to compare VTE outcomes and mortality by TS, (reference =
enoxaparin). Life-years gained (LYG) from decreased mortality
were estimated from actuarial tables. Sensitivity analyses were
performed on costs and rates of VTE events. RESULTS: Enox-
aparin (n = 750), dalteparin (n = 117), and enoxaparin with
heparin (n = 151) were associated with signiﬁcantly (LR,
P < 0.001) fewer DVTs (1.7%, 2.6%, and 3.3%, respectively)
than enoxaparin plus warfarin (n = 128, 20.1%); with an odds
ratio (OR) and 95% conﬁdence interval (95% CI) equal to 5.1
and 2.9–8.9. PE rate was also signiﬁcantly higher (LR, P = 0.002)
with enoxaparin plus warfarin OR = 6.5, 95% CI = 2.3–18.3.
Dalteparin was least costly and dominated (less costly/more
effective) enoxaparin plus warfarin. Compared to dalteparin,
enoxaparin was associated with an incremental cost-effective
ratio (ICER) of $264,449/DVT avoided and $7,691/LYG.
Fondaparinux was estimated to result in an ICER of $561,645/
DVT avoided and $2,752/LYG. The model was insensitive to
changes in VTE rates, but sensitive to decreases in costs of VTEs
or drugs. CONCLUSION: Dalteparin was most cost-effective,
followed by fondaparinux (based upon clinical trials) and enox-
aparin. Enoxaparin plus warfarin was dominated by other TS.
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OBJECTIVES: The aim of this study was to analyse the cost-
effectiveness of consecutive supplementing of the Framingham
scoring (FRS) algorithm for coronary artery disease (CAD) risk
assessment with apolipoproteins B and A-I (apoA-I and apoB),
the apo (a) phenotype, lipoprotein (a), and high sensitivity C-
reactive protein (hs-CRP). The perspective of the analysis is the
clinical laboratory setting. METHODS: The study is prospective
diagnosing of 221 CAD patients and 289 controls. First line
testing followed the guidelines for risk assessment based on FRS.
Risk factors included in the FRS are: age, total cholesterol, high
density cholesterol, systolic blood pressure, treatment for hyper-
tension and cigarette smoking. FRS classiﬁes individuals into
those with 10-year risk for CAD of >20% event risk (high risk
group), 10–20% event risk (intermediate risk group) and <10%
event risk (low risk group). The FRS algorithm was supple-
mented with apolipoproteins, lipoproteins and hs-CRP and the
effectiveness was measured in number needed to diagnose
(NND). Total cost of diagnostic procedure was calculated on the
basis of the consumed resources for diagnostic tests, labor time,
and consumables. To evaluate the additional number needed to
be diagnosed for successful CAD risk establishment was per-
formed and incremental cost-effectiveness analysis. RESULTS:
A diagnostic strategy employing FRS followed by apoA-I had
lowest cost per additionally successfully diagnoses patient than
the same strategy followed by hs-CRP in the low (2.63 vs. 24.47
euros) and intermediate risk groups (2.93 vs. 122.86 euros). In
the high-risk group the diagnostic strategy employing apo A-I
was the cost-effective strategy. It had a lower ICER (-9.14 euros)
than the strategy employing hs-CRP (7.16 euros). CONCLU-
SION: Cost-effectiveness analysis of different diagnostic markers
results in improved identiﬁcation of at-risk patients at a lower
health cost for society. In the clinical laboratory setting it is
sufﬁcient to determine apoA-I concentration in addition to FRS
for CAD risk assessment.
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OBJECTIVES: Several clinical trials have shown the added
beneﬁt of clopidogrel in reducing the risk of ischemic events in
patients with non-ST-segment elevation myocardial infarction
(NSTEMI) and unstable angina as well as in ST-segment eleva-
tion myocardial infarction (STEMI). The objective of our study
was to evaluate the cost-effectiveness of clopidogrel in the man-
agement of patients with STEMI in Hungary. METHODS: The
analysis is based on the CLARITY and COMMIT trials, which
have investigated the effect of clopidogrel in patients with
STEMI. A combined decision tree and Markov model was devel-
oped. Effectiveness was measured as the number of life-years
gained (LYG) from clopidogrel treatment. Since existing evidence
indicates similar long-term outcomes after STEMI and NSTEMI,
data from the long-term NSTEMI CURE trial was combined
with one-month data from CLARITY and COMMIT to model
the effect of treatment up to one year. The risk of death, MI and
stroke in an untreated population and long-term survival were
derived from the Swedish Hospital Discharge and Cause of
Death registers. The model was run separately for the two
STEMI trials. A payer perspective was chosen for the analysis.
Costs are reported in Hungarian Forints (HUF) at 2006 price
levels. The annual discount rate was set to 5 percent. RESULTS:
Treatment with clopidogrel for up to one year results in 0,086
LYG at an incremental cost of €40 (HUF 9,820) when using a
patient cohort with the same characteristics and event rates as the
CLARITY population. By comparison, using data from the
COMMIT study, clopidogrel treatment results in 0.134 LYG at
an incremental cost of €572 (HUF 140,662). The incremental
cost-effectiveness ratios thus amount to €464 (HUF114,007)/
LYG and €4,281 (HUF1,052,071)/LYG, respectively. CONCLU-
SION: Treatment of STEMI patients with clopidogrel for up
to one year is cost-effective in Hungary with predicted cost-
effectiveness ratios well below generally accepted thresholds
(€20,000–30,000).
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OBJECTIVES: Obesity is associated with a high risk for diabetes
type-2 (T2DM) and cardiovascular diseases. Rimonabant, the
ﬁrst cannabinoid-1receptor blocker, is a new therapeutic option
for overweight patients with additional risk factors and obese
patients. In the RIO-studies rimonabant showed signiﬁcant
reductions in weight and waist circumference, an improvement
of HbA1c, HDL and triglycerides, when added to diet and exer-
cise. The aim of this study was to evaluate the cost-effectiveness
of rimonabant in patients with BMI 30 kg/m2 or BMI
>27 kg/m2 and additional risk factors from the German SHI-
perspective. METHODS: The previously developed Rainbow
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